Therefore, this pre-clinical study appears to provide a scientific rationale for using selective BCR–ABL/JAK2 dual inhibition as a promising anti-LPCs therapeutic approach for patients with de novo Ph+ALL. The gene discussed is JAK2; the disease is acute lymphoblastic leukemia.